A phase I/II study of S-1 and irinotecan (IRIS) combined with cetuximab in patients with RAS wild-type metastatic colorectal cancer (KSCC1401)

被引：0

作者：

Hironori Samura

Eiji Oki

Hiroshi Okumura

Takefumi Yoshida

Seiichiro Kai

Kazuma Kobayashi

Tatsuya Kinjo

Shinichiro Mori

Tetsuo Tohyama

Kippei Ohgaki

Hirofumi Kawanaka

Akitaka Makiyama

Norio Ureshino

Masahito Kotaka

Takayuki Shimose

Koji Ando

Hiroshi Saeki

Hideo Baba

Yoshihiko Maehara

Masaki Mori

机构：

[1] Urazoe General Hospital,Gastrointestinal Disease Center

[2] Kyushu University,Department of Surgery and Science, Graduate School of Medical Sciences

[3] Kagoshima Koseiren Hospital,Department of Surgery

[4] Social Insurance Tagawa Hospital,Department of Surgery

[5] Nakatsu Municipal Hospital,Department of Surgery

[6] Nagasaki University Graduate School of Biomedical Sciences,Department of Surgery

[7] University of the Ryukyu Faculty of Medicine,Division of Digestive and General Surgery

[8] Kagoshima University Graduate School of Medical and Dental Sciences,Department of Digestive Surgery, Breast and Thyroid Surgery

[9] Nakagami Hospital,Department of Surgery

[10] Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers,Department of Surgery

[11] National Hospital Organization Beppu Medical Center,Clinical Research Institute and Department of Surgery

[12] Japan Community Healthcare Organization Kyushu Hospital,Department of Hematology/Oncology

[13] Gifu University Hospital,Cancer Center

[14] Department of Medical Oncology,Gastrointestinal Cancer Center

[15] Sano Hospital,Department of General Surgical Science Graduate School of Medicine

[16] Clinical Research Support Center Kyushu,Department of Gastroenterological Surgery, Graduate School of Medical Sciences

[17] Gunma University,undefined

[18] Kumamoto University,undefined

来源：

Cancer Chemotherapy and Pharmacology | 2020年 / 86卷

关键词：

Metastatic colorectal cancer; Cetuximab; S-1; Irinotecan; Oral fluoropyrimidine;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：285 / 294

页数：9

共 512 条

[1]

Hashiguchi Y(2019)Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer Int J Clin Oncol 15 019-01485

[2]

Muro K(2018)Shorter survival in adolescent and young adult patients, compared to adult patients, with stage IV colorectal cancer in Japan BMC Cancer 18 334-237

[3]

Saito Y(2004)FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study J Clin Oncol 22 229-2019

[4]

Ito Y(2008)Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J Clin Oncol 26 2013-119

[5]

Ajioka Y(2009)Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer Oncology 77 113-1417

[6]

Hamaguchi T(2009)Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 360 1408-631

[7]

Hasegawa K(2018)S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial Ann Oncol 29 624-5917

[8]

Hotta K(2008)Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials J Clin Oncol 26 5910-64

[9]

Ishida H(2011)XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results Br J Cancer 105 58-264

[10]

Ishiguro M(2006)Commentary on a phase III trial of bevacizumab plus XELOX or FOLFOX4 for first-line treatment of metastatic colorectal cancer: the NO16966 trial Clin Colorectal Cancer 6 261-2516

← 1 2 3 4 5 6 7 8 9 10 →